Unión Europea - español - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - enfermedad de fabry - otros tracto alimentario y metabolismo de los productos, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).